20:51 , Mar 23, 2017 |  BC Week In Review  |  Clinical News

AEVI-001: Ph II/III SAGA data

Top-line data from the double-blind, U.S. Phase II/III SAGA trial in 96 evaluable ADHD patients ages 12-17 with genetic disorders impacting mGluRs showed that twice-daily oral AEVI-001 missed the primary endpoint of reducing ADHD-RS total...
22:39 , Mar 20, 2017 |  BC Extra  |  Clinical News

Aevi plummets after ADHD candidate fails in Phase II/III

Aevi Genomic Medicine Inc. (NASDAQ:GNMX) shed $3.23 (59%) to $2.21 on Monday after it said AEVI-001 missed the primary endpoint in the Phase II/III SAGA study to treat ADHD in adolescent patients with metabotropic glutamate...
21:45 , Feb 1, 2017 |  BC Week In Review  |  Clinical News

AEVI-001: Ph I/II started

Aevi began an open-label, U.S. Phase I/II trial evaluating 50, 100, 200 and 400 mg oral AEVI-001 twice daily over 5 weeks in about 12 patients ages 12-17 with a 22q11.2 deletion and diagnosed with...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Clinical News

NFC-1: Phase II/III started

Medgenics began the double-blind, placebo-controlled, U.S. Phase II/III SAGA trial to evaluate 100, 200 and 400 mg oral NFC-1 twice daily for 6 weeks in 90 patients ages 12-17. In 1H17, Medgenics plans to start...
07:00 , May 26, 2016 |  BC Innovations  |  Targets & Mechanisms

Dissociating ketamine

For decades, researchers have struggled with the conundrum of how to exploit the antidepressant effects of ketamine without incurring its psychedelic effects. Now, a group from NIH and the University of Maryland has shown that...
08:00 , Mar 3, 2016 |  BC Innovations  |  Targets & Mechanisms

Rescue mission

A pair of preclinical studies published last month on the autism target SHANK3 provide what might be the most meaningful progress for patients since the gene was linked with the disease over a decade ago....
07:00 , Aug 20, 2012 |  BioCentury  |  Emerging Company Profile

Mind-NRG: New neuroprotection

Approved therapies for Parkinson's disease treat motor symptoms but cannot stop the loss of dopaminergic neurons that causes them....
07:00 , Aug 13, 2012 |  BioCentury  |  Strategy

Spinning Out mGluRs

Although Merck Serono S.A. decided to drop Parkinson's disease from its neuroscience portfolio, its preclinical compounds targeting metabotropic glutamate receptors for PD will continue to live on in a newco called Prexton Therapeutics S.A. Backed...
08:00 , Jan 5, 2012 |  BC Innovations  |  Targets & Mechanisms

Fine-tuning mGluRs

Studies by two American teams have converged on a family of metabotropic glutamate receptors as players in attention deficit hyperactivity disorder and autism spectrum disorder. 1,2 The findings build an argument for agonizing the receptors...
07:00 , Jul 11, 2011 |  BC Week In Review  |  Company News

Addex neurology news

Addex plans to restructure and reduce headcount by about 25% to reduce costs. The company expects the changes to produce annual savings of CHF8 million ($9.4 million) and extend the company's cash through the end...